Hepatitis B antigen and antibody in active chronic hepatitis and other liver diseases in Australia. A multicenter collaborative study.
In a multicenter cooperative study, sera from 85 patients with active chronic hepatitis (ACH) were examined for the presence of hepatitis B (Australia) antigen (HBAg) by radioimmunoassay (RIA) and antibody to HBAg (anti-HBAg) by RIA and passive hemagglutination (PHA), the most sensitive currently available techniques. In addition, sera from 83 patients with other liver diseases 98 other hospital patients, and 67 healthy controls were tested. HBAg was detected in 3 of the 85 patients (four percent) with ACH. In a further 3 patients (four percent) anti-HBAg was detected. Thus, 6 patients with ACH (seven percent) had evidence of present or prior infection with the hepatitis B virus (HBV). HBAg was also detected in 7 of the patients with other liver diseases, 2 of the other hospital patients, and none of the healthy controls. Anti-HBAg was detected in 17 of the non-ACH subjects. These results indicate that neither persistent nor prior self-limited infection with HBV is a major factor in the pathogenesis of ACH in Australia.
D000208:Acute Disease; D000906:Antibodies / Q000032:analysis*; D001315:Australia; D002908:Chronic Disease; D003168:Complement Fixation Tests; D006386:Hemagglutination Tests; D006505:Hepatitis / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006511:Hepatitis B Antigens / Q000032:analysis*; D006801:Humans; D005779:Immunodiffusion; D007122:Immunoelectrophoresis; D008107:Liver Diseases / Q000276:immunology*; D011863:Radioimmunoassay
D000906:Antibodies; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens